Cargando…

Production of a cellular product consisting of monocytes stimulated with Sylatron(®) (Peginterferon alfa-2b) and Actimmune(®) (Interferon gamma-1b) for human use

BACKGROUND: Monocytes are myeloid cells that reside in the blood and bone marrow and respond to inflammation. At the site of inflammation, monocytes express cytokines and chemokines. Monocytes have been shown to be cytotoxic to tumor cells in the presence of pro-inflammatory cytokines such as Interf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Green, Daniel S., Nunes, Ana T., Tosh, Kevin W., David-Ocampo, Virginia, Fellowes, Vicki S., Ren, Jiaqiang, Jin, Jianjian, Frodigh, Sue-Ellen, Pham, Chauha, Procter, Jolynn, Tran, Celina, Ekwede, Irene, Khuu, Hanh, Stroncek, David F., Highfill, Steven L., Zoon, Kathryn C., Annunziata, Christina M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Methodology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419352/ https://www.ncbi.nlm.nih.gov/pubmed/30871636 http://dx.doi.org/10.1186/s12967-019-1822-6

Ejemplares similares

A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron(®) (Peginterferon alfa-2b) and Actimmune(®) (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer
por: Green, Daniel S., et al.
Publicado: (2018)

Counter-flow elutriation of clinical peripheral blood mononuclear cell concentrates for the production of dendritic and T cell therapies
por: Stroncek, David F, et al.
Publicado: (2014)

Enhanced clinical-scale manufacturing of TCR transduced T-cells using closed culture system modules
por: Jin, Jianjian, et al.
Publicado: (2018)

Cost-Efficacy Analysis of Peginterferon alfa-2b plus Ribavirin Compared With Peginterferon alfa-2a plus Ribavirin for the Treatment of Chronic Hepatitis C
por: Malone, Daniel C., et al.
Publicado: (2005)

Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells
por: Stroncek, David F., et al.
Publicado: (2017)

Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil
por: Barros, Fabio MR, et al.
Publicado: (2013)

A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
por: Brohl, Andrew S., et al.
Publicado: (2016)

The establishment of a bank of stored clinical bone marrow stromal cell products
por: Sabatino, Marianna, et al.
Publicado: (2012)

Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B
por: Marcellin, Patrick, et al.
Publicado: (2020)

Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C
por: Pouresmaeeli, Mahdiyar, et al.
Publicado: (2015)

Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection
por: Masaki, Keiichi, et al.
Publicado: (2015)

Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis
por: Jin, Ping, et al.
Publicado: (2008)

Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients
por: Marcellin, Patrick, et al.
Publicado: (2012)

Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus
por: Kim, Yu Jin, et al.
Publicado: (2011)

Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis
por: Ahn, Sang Hoon, et al.
Publicado: (2018)

Comparison of peginterferon alfa-2a and alfa-2b for treatment of patients with chronic hepatitis C: a retrospective study using the Japanese Interferon Database
por: Sato, Izumi, et al.
Publicado: (2014)

Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a
por: El-Lababidi, Rania M., et al.
Publicado: (2020)

No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B
por: Wei, Lai, et al.
Publicado: (2018)

Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a
por: Jia, Wen, et al.
Publicado: (2019)

Significance of T-Cell Subsets for Clinical Response to Peginterferon Alfa-2a Therapy in HBeAg-Positive Chronic Hepatitis B Patients
por: Zhu, Li, et al.
Publicado: (2022)

A meta-analysis that compares the use of either peginterferon-α2a or peginterferon-α2b plus ribavirin for HCV infection
por: Xiao, Nan, et al.
Publicado: (2010)

A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in hepatitis B e antigen-negative chronic hepatitis B
por: Lampertico, Pietro, et al.
Publicado: (2018)

Population pharmacokinetics of peginterferon α2a in patients with chronic hepatitis B
por: Bi, Jingfeng, et al.
Publicado: (2017)

Expression Pattern of Cytokines in Patients with Chronic Hepatitis B Receiving PEGinterferon Therapy
por: Chen, Shao-Long, et al.
Publicado: (2023)

A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C
por: Flisiak, Robert, et al.
Publicado: (2016)

CXCL9 Associated with Sustained Virological Response in Chronic Hepatitis B Patients Receiving Peginterferon Alfa-2a Therapy: A Pilot Study
por: Lee, I-Cheng, et al.
Publicado: (2013)

Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa
por: Liu, Chen-Hua, et al.
Publicado: (2014)

Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B
por: Sonneveld, Milan J., et al.
Publicado: (2010)

Hepatitis B Surface Antigen (HBsAg) Kinetics in Chronic Hepatitis B Patients during Peginterferon Treatment
por: Wang, Kaifa, et al.
Publicado: (2020)

Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B
por: Lok, Anna S., et al.
Publicado: (2019)

Efficacy of Peginterferon alfa-2b in Nucleoside Analogue Experienced Patients with Negative HBeAg and Low HBsAg: A Non-Randomized Clinical Trial
por: Chen, Jun, et al.
Publicado: (2021)

The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study
por: El Raziky, Maissa, et al.
Publicado: (2013)

Efficacy and Tolerability of Peginterferon α-2a and Peginterferon α-2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials
por: Yang, Zongguo, et al.
Publicado: (2013)

Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg‐positive chronic hepatitis B
por: van Campenhout, Margo J. H., et al.
Publicado: (2020)

Interleukin-28B Polymorphisms Predict the Efficacy of Peginterferon Alpha in Patients With Chronic Hepatitis B: A Meta-Analysis
por: Ying, Sang-Yu, et al.
Publicado: (2021)

Levels of Antibodies to Hepatitis B Core Antigen Are Associated With Liver Inflammation and Response to Peginterferon in Patients With Chronic Hepatitis B
por: Brakenhoff, Sylvia M, et al.
Publicado: (2022)

Point-of-care cell therapy manufacturing; it’s not for everyone
por: Stroncek, David F., et al.
Publicado: (2022)

Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis
por: Druyts, Eric, et al.
Publicado: (2012)

Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C
por: Jeong, Seok Hoo, et al.
Publicado: (2012)

Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study
por: Hayashi, Norio, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6hclths90o8otonlp8cf9qugnd